As tariffs, HHS workforce cuts and the ouster of CBER Director Peter Marks threaten the “lifeblood” of the cell and gene ...

Big compounders will have until May 22 to stop producing and dispensing compounded semaglutide, while smaller, state-run ...

The transaction, which sources say could be agreed upon as soon as Monday, would price SpringWorks at $47 per share, totaling ...

Biotech was starting to show signs of recovery after years of investor pullback—until new tariffs and economic uncertainty ...

The cell and gene therapy company is cutting 47 employees and its entire lupus program to focus resources on two CAR Ts. The ...

As Marty Makary nears the end of his first month on the job, the FDA Commissioner sat down for two interviews, offering ...

While AbbVie handily beat expectations this quarter, the company faces declining Humira sales and a challenged aesthetics ...

The hold, placed by the FDA on an early-stage clinical trial of an experimental BET inhibitor, stems from a recent ...

Presentations at this year’s American Association for Cancer Research meeting could have a broad impact on the treatment ...

Granite will focus on two antibody therapies, both targeting crucial players in the inflammatory cascade to address ...

President Donald Trump in February threatened top pharma leaders, including Eli Lilly CEO David Ricks, with tariffs unless ...

The FDA is asking Novavax for a non-mandatory postmarketing commitment to produce additional clinical data for its ...